Quince Therapeutics, Inc. (QNCX)

Market Cap	5.51M -90.8%
Revenue (ttm)	n/a
Net Income	-56.98M
EPS	-1.21
Shares Out	55.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,855,017
Open	0.1000
Previous Close	0.1023
Day's Range	0.0930 - 0.1000
52-Week Range	0.0800 - 4.5500
Beta	1.33
Analysts	Hold
Price Target	n/a
Earnings Date	May 12, 2026

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://www.quincetx.com